Injectable HIV Therapy Outperforms Daily Pills in Patients With Detectable Virus
Injectable HIV Therapy Outperforms Daily Pills in Patients With Detectable Virus
ViiV Healthcare has reported positive Phase IIIb results for Cabenuva, a long-acting injectable HIV treatment that achieved superior viral suppression compared with daily oral antiretroviral therapy in people who entered the study with detectable HIV-1.
Announced on October 6, 2026, the findings come from the international CROWN study and could support further evaluation of injectable treatment for people who have struggled to achieve viral suppression with daily medication.
CROWN Trial Addresses an Unmet Need in HIV Treatment
Modern antiretroviral therapy can control HIV and help people live longer, healthier lives. However, maintaining viral suppression can be challenging for some patients because of medication adherence difficulties, treatment-related barriers and other personal or structural factors.
When HIV remains detectable despite treatment, patients may face ongoing health risks and require adjustments to their treatment plans. CROWN was designed to investigate whether a long-acting injectable regimen could help address this challenge.
The Phase IIIb study enrolled approximately 326 adults and adolescents living with HIV-1 across eight countries and 85 clinical sites. Participants had a history of antiretroviral treatment but still had detectable virus when entering the study.
The trial evaluated whether patients could begin long-acting cabotegravir plus rilpivirine directly, rather than first achieving viral suppression with oral medication. Participants also had to meet specific resistance-related eligibility criteria.
How the Injectable Treatment Works
Cabenuva combines two antiretroviral medicines:
Cabotegravir: An integrase strand transfer inhibitor that blocks an enzyme HIV needs to integrate its genetic material into human cells.
Rilpivirine: A non-nucleoside reverse transcriptase inhibitor that interferes with another essential step in the virus's replication process.
Together, the medicines target different stages of the HIV life cycle. The long-acting formulation is administered through intramuscular injections, reducing the need to take HIV treatment tablets every day.
In the CROWN study, the regimen was administered six times per year. This schedule may offer practical advantages for eligible patients who find daily oral treatment difficult to maintain, although regular clinical appointments remain necessary.
Trial Meets Its Primary Endpoint
ViiV Healthcare reported that CROWN met its primary endpoint, demonstrating superior viral suppression at six months compared with standard-of-care daily oral antiretroviral therapy.
The result is notable because the study examined a population with detectable HIV at treatment initiation. Previous evidence supporting long-acting cabotegravir and rilpivirine largely came from patients who had already achieved viral suppression or from studies involving different treatment circumstances.
However, the company has not yet released the complete numerical results in its announcement. Detailed efficacy and safety findings are expected at an upcoming scientific meeting. The available announcement therefore does not provide enough information to independently assess the size of the treatment benefit or all relevant clinical outcomes.
How CROWN Builds on the LATITUDE Study
The findings follow the earlier LATITUDE Phase 3 trial, which evaluated long-acting cabotegravir plus rilpivirine in people with HIV who experienced difficulties adhering to oral treatment.
In LATITUDE, participants first received adherence support and oral therapy. Those who achieved a specified level of viral suppression could then be randomized to injectable treatment or continued standard oral care.
At 48 weeks, the cumulative risk of regimen failure was 22.8% in the injectable group, compared with 41.2% in the daily oral therapy group. Regimen failure included virological failure or discontinuation of treatment. These results were published in The New England Journal of Medicine in February 2026.
CROWN extends this research by studying people who still had detectable virus when they entered the trial. The two studies address related but distinct clinical situations, so their findings should not be treated as interchangeable.
Regulatory Status and Safety Considerations
Cabenuva is already approved in the United States for eligible adults and adolescents aged 12 years or older who weigh at least 35 kilograms and have achieved viral suppression on a stable antiretroviral regimen, without a history of treatment failure or known or suspected resistance to either medicine.
Starting Cabenuva in patients who have detectable HIV remains investigational and is not covered by the currently approved indication. The CROWN findings will need to undergo further assessment before any potential change to the product's authorized use.
The treatment also requires careful patient selection and monitoring. Potential adverse effects include injection-site reactions, headache, fever, fatigue and nausea. Drug interactions, hypersensitivity reactions and the risk of resistance if injections are missed or treatment is discontinued without appropriate replacement therapy are important considerations.
Patients should not switch or stop prescribed HIV medication without consulting their healthcare professional.
What the Results Could Mean for HIV Care
If further analysis and regulatory review support the findings, long-acting injectable therapy could expand treatment options for selected people who have difficulty maintaining viral suppression with daily pills.
The approach may reduce the burden of daily medication and help address some adherence barriers. Nevertheless, injections require reliable access to healthcare services, attendance at scheduled appointments and careful management if treatment is delayed or discontinued.
The results also highlight the importance of developing treatment strategies for people who do not respond adequately to standard approaches. Viral resistance, individual treatment history and patient circumstances will remain central to choosing an appropriate regimen.
Next Steps for ViiV Healthcare
ViiV Healthcare, majority-owned by GSK, said it intends to share the CROWN findings with health authorities for regulatory review. Full trial data will be needed to clarify the magnitude and durability of viral suppression, characterize safety outcomes and establish how the findings may influence treatment guidance.
For now, CROWN provides encouraging evidence for investigating long-acting injectable HIV treatment in a population with ongoing viraemia. Whether it changes clinical practice will depend on the complete results and subsequent regulatory decisions.
Sources:
Antimony Trioxide (99.5%) - China
Found this useful?
